Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Roche reports Q3 earnings - looks to Tecentriq for future
View:
Post by Noteable on Oct 25, 2022 5:23pm

Roche reports Q3 earnings - looks to Tecentriq for future

Roche's pharma revenues declined in the third quarter, but the Swiss major pharma company is looking towards their immune checkpoint inhibitor Tecentriq in adjuvant settings to boost future revenues.

Consequently, ONCY's pancreatic results from the Goblet Phase 2 clinical study could be what leads Roche's gains involving Teccentriq in combination with ONCY's pelareorep.

We will gain more insight into the positive results of the Goblet panceatic cancer cohort on November 11th at the SITC 2022 - 37th Annual Meeting
.


https://www.oncolyticsbiotech.com/press-releases/detail/582/oncolytics-biotech-announces-upcoming-presentations-at
Comment by Noteable on Oct 25, 2022 5:36pm
London, UK and Boston, MA – 18 October 2022: The global pharmaceutical industry is set to see sales grow by an annualised 6% between 2022 and 2028, according to the latest World Preview published by Evaluate Ltd. The annual report, which details the future of the biopharmaceutical sector, forecasts industry revenues of $1.6 Trillion in six years’ time. Mike ...more  
Comment by Buckhenry on Oct 25, 2022 6:18pm
noteable gets the prestigious fickle finger award for posting the most stuff that has no bearing on oncy...
Comment by Noteable on Oct 27, 2022 12:48pm
October 26, 2022 - https://www.evaluate.com/vantage/articles/news/trial-results/astra-beats-roche-twice-day
Comment by jimsenior on Oct 31, 2022 10:07am
Added some shares this morning! Bonne chance.
Comment by Noteable on Oct 31, 2022 12:12pm
All I saw on the TSX early this morning was Quebec based Desjardins Securities selling into the bid. I don't know how you "Machiavelli senior" could have been doing any "Bonne chance" buying.
Comment by jimsenior on Oct 31, 2022 12:30pm
Do not know who sold them to me, but I bought 800 shares through TD.  Yes this morning. As you know I was undecided, and decided to add. One of your posts on sequencing was influential in my thinking I said Bonne Chance because I am under no illusions that that a share price increase is guaranteed. This is a biotech and given the past performance, one needs to be careful. Any further ...more  
Comment by Noteable on Oct 31, 2022 12:39pm
Nonsense from me ?? !! Give your head a shake !
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities